San Francisco-based FibroGen Gets SFDA Nod Through Green Channel Procedure
This article was originally published in PharmAsia News
Executive Summary
HONG KONG - San Francisco-based FibroGen announced that Chinese regulators approved the start of clinical trials of novel therapy FG-4592 for anemia associated with chronic kidney disease. The approval was expedited through China's two-year-old special approval procedure, or "green channel.You may also be interested in...
Emerging Markets Earnings Roundup: AstraZeneca (Part 12)
Who’s on first in China? That might be the a good question for AstraZeneca’s chief Pascal Soriot after the CEO of Pfizer also went out of his way to highlight second quarter success in the Middle Kingdom.
How Much Risk Should Big Pharma Accept To Close Deals In China?
How Much Risk Should Big Pharma Accept To Close Deals In China?
Need a specific report? 1000+ reports available
Buy Reports